Evidence map›Paper›PMID 19147747›Full record

ReviewClinical cancer research : an official journal of the American Association for Cancer Research2009

Clinical applications of metabolomics in oncology: a review.

Jennifer L Spratlin, Natalie J Serkova, S Gail Eckhardt

Abstract readReview
In one paragraph

Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 338 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
338citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

338 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Prediagnostic Plasma Metabolite Profiles and Prediction of Hepatocellular Carcinoma Risk: The Multiethnic Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  10. Review
  11. Metabolic Control of Membrane Lipid Asymmetry in Cancer.International journal of molecular sciences · 2026
    Review
  12. Scientific reports · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Metabolomics: Fundamentals, Methods, Analysis, Limits, and Recommendations.Advances in experimental medicine and biology · 2026
    Review
  19. Article
  20. Review

278 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jennifer L SpratlinDepartment of Medical Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA. jennspra@cancerboard.ab.ca
Natalie J Serkova
S Gail Eckhardt

Funding

Development of Mechanism-Based Anticancer TherapyK24CA106349 · NCI · UNIVERSITY OF COLORADO DENVER · PI ECKHARDT, S. GAIL · 2005 to 2009
$926k
Metabolic Signature of Imatinib ResistanceR21CA108624 · NCI · UNIVERSITY OF COLORADO DENVER · PI SERKOVA, NATALIE J · 2005 to 2006
$262k
NCI NIH HHS K24 CA106349NCI NIH HHS R21 CA108624
6 · The paper itself

Abstract

Metabolomics, an omic science in systems biology, is the global quantitative assessment of endogenous metabolites within a biological system. Either individually or grouped as a metabolomic profile, detection of metabolites is carried out in cells, tissues, or biofluids by either nuclear magnetic resonance spectroscopy or mass spectrometry. There is potential for the metabolome to have a multitude of uses in oncology, including the early detection and diagnosis of cancer and as both a predictive and pharmacodynamic marker of drug effect. Despite this, there is lack of knowledge in the oncology community regarding metabolomics and confusion about its methodologic processes, technical challenges, and clinical applications. Metabolomics, when used as a translational research tool, can provide a link between the laboratory and clinic, particularly because metabolic and molecular imaging technologies, such as positron emission tomography and magnetic resonance spectroscopic imaging, enable the discrimination of metabolic markers noninvasively in vivo. Here, we review the current and potential applications of metabolomics, focusing on its use as a biomarker for cancer diagnosis, prognosis, and therapeutic evaluation.

Indexed as

MetabolomeBiomarkers, TumorComputational BiologyDrug DiscoveryHumansMagnetic Resonance SpectroscopyMedical OncologyMetabolomicsModels, BiologicalNeoplasmsPhenotypePositron-Emission TomographySystems BiologyBiomarkers, Tumor

Identifiers

PMID19147747
PMCPMC2676437

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.